Is Pfizer Stock a Good Investment?

Pfizer Investment Advice

PFE

To provide specific investment advice or recommendations on Pfizer Inc stock, we recommend investors consider the following general factors when evaluating Pfizer Inc. This will help you to make an informed decision on whether to include Pfizer in one of your diversified portfolios:

Examine Pfizer's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
Research Pfizer's leadership team and their track record. Good management can help Pfizer navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Pfizer's business and its evolving consumer preferences.
Compare Pfizer's performance and market position to its competitors. Analyze how Pfizer is positioned in terms of product offerings, innovation, and market share.
Check if Pfizer pays a dividend and its dividend yield and payout ratio.
Review what financial analysts are saying about Pfizer's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.

It's important to note that investing in Pfizer Inc stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Pfizer Inc is a good investment.

Sell

Buy

Strong Hold

Our recommendation module complements current analysts and expert consensus on Pfizer. It analyzes the company potential to grow using all fundamental, technical, and market related data available at the time. To make sure Pfizer is not overpriced, please check all Pfizer Inc fundamentals, including its cash and equivalents, earnings per share, and the relationship between the revenue and current ratio . Given that Pfizer Inc has a price to earning of 9.48 X, we recommend you to check out Pfizer Inc market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your recent risk tolerance and investing horizon.

Market Performance	Very Weak	Details
Volatility	Very steady	Details
Hype Condition	Low key	Details
Current Valuation	Undervalued	Details
Odds Of Distress	Low	Details
Economic Sensitivity	Follows the market closely	Details
Investor Sentiment	Impartial	Details
Analyst Consensus	Buy	Details
Financial Strenth (F Score)	Healthy	Details
Financial Leverage	Not Rated	Details
Reporting Quality (M-Score)	Unlikely Manipulator	Details

Examine Pfizer Stock

Researching Pfizer's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 68.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.51. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pfizer Inc has Price/Earnings To Growth (PEG) ratio of 0.61. The entity last dividend was issued on the 9th of May 2025. The firm had 1054:1000 split on the 17th of November 2020.

To determine if Pfizer is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Pfizer's research are outlined below:

	Pfizer Inc generated a negative expected return over the last 90 days
	About 68.0% of the company shares are owned by institutional investors
	On 13th of June 2025 Pfizer paid $ 0.43 per share dividend to its current shareholders
	Latest headline from finance.yahoo.com: Lantheus Holdings Joins FIBRE Consortium To Transform Fibrotic Disease Treatment

Pfizer Quarterly Cost Of Revenue

2.85 Billion

Pfizer uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Pfizer Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pfizer's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.

	7th of May 2024 Upcoming Quarterly Report	View
	6th of August 2024 Next Financial Report	View
	31st of March 2024 Next Fiscal Quarter End	View
	4th of February 2025 Next Fiscal Year End	View
	31st of December 2023 Last Quarter Report	View
	31st of December 2023 Last Financial Announcement	View

Earnings surprises can significantly impact Pfizer's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Pfizer's investors have experienced.

Reported	Fiscal Date	Estimated EPS	Reported EPS	Surprise
1999-07-19	1999-06-30	0.17	0.19	0.02	11
1998-10-13	1998-09-30	0.19	0.17	-0.02	10
1998-07-09	1998-06-30	0.15	0.17	0.02	13
2000-04-18	2000-03-31	0.25	0.28	0.03	12
2009-04-28	2009-03-31	0.49	0.54	0.05	10
2008-01-23	2007-12-31	0.47	0.52	0.05	10
2021-02-02	2020-12-31	0.48	0.42	-0.06	12
2018-01-30	2017-12-31	0.56	0.62	0.06	10

Pfizer Target Price Consensus

Pfizer target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Pfizer's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.

Buy

Most Pfizer analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Pfizer stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Pfizer Inc, talking to its executives and customers, or listening to those companies' conference calls.

Macroaxis Advice Exposure Valuation

Pfizer Target Price Projection

Pfizer's current and average target prices are 23.97 and 29.24, respectively. The current price of Pfizer is the price at which Pfizer Inc is currently trading. On the other hand, Pfizer's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Pfizer Market Quote on 23rd of June 2025

Low Price	23.77	Odds
High Price	24.09	Odds

23.97 Target Price

Analyst Consensus On Pfizer Target Price

Low Estimate	26.61	Odds
High Estimate	32.45	Odds

29.2387

Historical

Lowest Forecast 26.61

Target Price 29.24

Highest Forecast 32.45

Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Pfizer Inc and the information provided on this page.

Pfizer Analyst Ratings

Pfizer's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Pfizer stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Pfizer's financials, market performance, and future outlook by experienced professionals. Pfizer's historical ratings below, therefore, can serve as a valuable tool for investors.

Know Pfizer's Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Pfizer is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pfizer Inc backward and forwards among themselves. Pfizer's institutional investor refers to the entity that pools money to purchase Pfizer's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.

		Shares
Amundi	2025-03-31	52.1 M
Charles Schwab Investment Management Inc	2025-03-31	48 M
Fisher Asset Management, Llc	2025-03-31	47.4 M
Bank Of New York Mellon Corp	2025-03-31	38.7 M
Ubs Asset Mgmt Americas Inc	2025-03-31	38.7 M
Legal & General Group Plc	2025-03-31	37.1 M
Royal Bank Of Canada	2025-03-31	33.7 M
Jpmorgan Chase & Co	2025-03-31	32.3 M
Amvescap Plc.	2025-03-31	30.3 M
Vanguard Group Inc	2025-03-31	523.2 M
Blackrock Inc	2025-03-31	474.2 M

Note, although Pfizer's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Pfizer's market capitalization trends

The company currently falls under 'Mega-Cap' category with a total capitalization of 136.28 B.

Market Cap

126.06 Billion

Pfizer's profitablity analysis

	Last Reported	Projected for Next Year
Return On Tangible Assets	0.09	0.11
Return On Capital Employed	0.09	0.08
Return On Assets	0.04	0.04
Return On Equity	0.09	0.09

The company has Net Profit Margin of 0.13 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.35 %, which entails that for every 100 dollars of revenue, it generated $0.35 of operating income.

Determining Pfizer's profitability involves analyzing its financial statements and using various financial metrics to determine if Pfizer is a good buy. For example, gross profit margin measures Pfizer's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Pfizer's profitability and make more informed investment decisions.

Pfizer's Earnings Breakdown by Geography

Please note, the presentation of Pfizer's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pfizer's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Pfizer's management manipulating its earnings.

Evaluate Pfizer's management efficiency

Pfizer Inc has Return on Asset of 0.0479 % which means that on every $100 spent on assets, it made $0.0479 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0862 %, implying that it generated $0.0862 on every 100 dollars invested. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.11, whereas Return On Capital Employed is forecasted to decline to 0.08. At present, Pfizer's Intangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 107.5 B, whereas Non Currrent Assets Other are forecasted to decline to about 5.5 B.

	Last Reported	Projected for Next Year
Book Value Per Share	15.62	16.41
Tangible Book Value Per Share	(6.26)	(5.94)
Enterprise Value Over EBITDA	11.74	15.55
Price Book Value Ratio	1.70	1.62
Enterprise Value Multiple	11.74	15.55
Price Fair Value	1.70	1.62
Enterprise Value	83.2 B	87.3 B

The strategic decisions made by Pfizer management significantly impact its financial stability and market performance. Evaluating these factors helps determine whether the stock is a worthwhile investment.

Dividend Yield

0.0718

Forward Dividend Yield

0.0718

Forward Dividend Rate

1.72

Beta

0.491

Basic technical analysis of Pfizer Stock

As of the 23rd of June, Pfizer holds the Variance of 3.45, risk adjusted performance of (0.08), and Coefficient Of Variation of (1,946). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pfizer, as well as the relationship between them. Please check Pfizer Inc standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and kurtosis to decide if Pfizer Inc is priced some-what accurately, providing market reflects its current price of 23.97 per share. Given that Pfizer has information ratio of (0.07), we recommend you to check out Pfizer Inc's recent market performance to make sure the company can sustain itself at a future point.

Pfizer's insider trading activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pfizer insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pfizer's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pfizer insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

		Boshoff Christoffel over three months ago Disposition of 12038 shares by Boshoff Christoffel of Pfizer at 26.52 subject to Rule 16b-3
		John Young over a year ago Acquisition by John Young of tradable shares of Pfizer subject to Rule 16b-3

Pfizer's Outstanding Corporate Bonds

Pfizer issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pfizer Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pfizer bonds can be classified according to their maturity, which is the date when Pfizer Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

	PFIZER INC 4125 Corp Bond US717081ED10	View
	PFIZER INC 4 Corp Bond US717081EC37	View
	PFIZER INC 3 Corp Bond US717081EA70	View
	PFIZER INC 44 Corp Bond US717081DK61	View
	PFIZER INC 275 Corp Bond US717081DV27	View
	US717081DT70 Corp Bond US717081DT70	View
	PFIZER INC Corp Bond US717081EZ22	View
	PFE 175 18 AUG 31 Corp Bond US717081FB45	View

View All Pfizer Corporate Bonds

Understand Pfizer's technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing Pfizer's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

	Risk Adjusted Performance	(0.08)
	Market Risk Adjusted Performance	(0.14)
	Mean Deviation	1.45
	Coefficient Of Variation	(1,946)
	Standard Deviation	1.86
	Variance	3.45
	Information Ratio	(0.07)
	Jensen Alpha	(0.12)
	Total Risk Alpha	(0.13)
	Treynor Ratio	(0.15)
	Maximum Drawdown	7.35
	Value At Risk	(3.72)
	Potential Upside	2.66
	Skewness	(0.52)
	Kurtosis	0.379

	Risk Adjusted Performance	(0.08)
	Market Risk Adjusted Performance	(0.14)
	Mean Deviation	1.45
	Coefficient Of Variation	(1,946)
	Standard Deviation	1.86
	Variance	3.45
	Information Ratio	(0.07)
	Jensen Alpha	(0.12)
	Total Risk Alpha	(0.13)
	Treynor Ratio	(0.15)
	Maximum Drawdown	7.35
	Value At Risk	(3.72)
	Potential Upside	2.66
	Skewness	(0.52)
	Kurtosis	0.379

Consider Pfizer's intraday indicators

Pfizer intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pfizer stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

	Accumulation Distribution	0.0133
	Daily Balance Of Power	0.2813
	Rate Of Daily Change	1.0
	Day Median Price	23.93
	Day Typical Price	23.94
	Market Facilitation Index	0.32
	Price Action Indicator	0.085
	Period Momentum Indicator	0.09
	Relative Strength Index	42.24

Pfizer Corporate Filings

F4	17th of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities	View Verify
	16th of June 2025 Other Reports	View Verify
	30th of May 2025 Other Reports	View Verify
	20th of May 2025 Certification of the accuracy of the financial statements and disclosures	View Verify

Pfizer time-series forecasting models is one of many Pfizer's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Pfizer's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Pfizer Stock media impact

There is far too much social signal, news, headlines, and media speculation about Pfizer that are available to investors today. This information is accessible both publicly - through Pfizer's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Pfizer-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.

A primary focus of Pfizer news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Pfizer relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Pfizer's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Pfizer alpha.

Pfizer Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Pfizer can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.

Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Pfizer Inc Historical Investor Sentiment

Investor biases related to Pfizer's public news can be used to forecast risks associated with an investment in Pfizer. The trend in average sentiment can be used to explain how an investor holding Pfizer can time the market purely based on public headlines and social activities around Pfizer Inc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

Pfizer's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Pfizer and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Pfizer news discussions. The higher the estimate score, the more favorable the investor's outlook on Pfizer.

Pfizer Maximum Pain Price Across September 19th 2025 Option Contracts

Pfizer's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Pfizer close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Pfizer's options.

Pfizer Corporate Directors

Helen Hobbs	Independent Director	Profile
Shantanu Narayen	Lead Independent Director	Profile
James Smith	Independent Director	Profile
Susan DesmondHellmann	Independent Director	Profile

When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports: